BRPI1013227A2 - pró-fármacos transportadores de interferon alfa - Google Patents

pró-fármacos transportadores de interferon alfa

Info

Publication number
BRPI1013227A2
BRPI1013227A2 BRPI1013227A BRPI1013227A BRPI1013227A2 BR PI1013227 A2 BRPI1013227 A2 BR PI1013227A2 BR PI1013227 A BRPI1013227 A BR PI1013227A BR PI1013227 A BRPI1013227 A BR PI1013227A BR PI1013227 A2 BRPI1013227 A2 BR PI1013227A2
Authority
BR
Brazil
Prior art keywords
transporter
prodrugs
interferon alpha
interferon
alpha
Prior art date
Application number
BRPI1013227A
Other languages
English (en)
Inventor
Harald Rau
Silvia Kaden-Vagt
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of BRPI1013227A2 publication Critical patent/BRPI1013227A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI1013227A 2009-03-05 2010-03-04 pró-fármacos transportadores de interferon alfa BRPI1013227A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154449 2009-03-05
EP09180477 2009-12-22
PCT/EP2010/052745 WO2010100220A1 (en) 2009-03-05 2010-03-04 Interferon alpha carrier prodrugs

Publications (1)

Publication Number Publication Date
BRPI1013227A2 true BRPI1013227A2 (pt) 2016-03-29

Family

ID=42041523

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013227A BRPI1013227A2 (pt) 2009-03-05 2010-03-04 pró-fármacos transportadores de interferon alfa

Country Status (10)

Country Link
US (1) US20120058084A1 (pt)
EP (1) EP2403537A1 (pt)
JP (1) JP2012519666A (pt)
CN (1) CN102413843A (pt)
AU (1) AU2010220324A1 (pt)
BR (1) BRPI1013227A2 (pt)
CA (1) CA2753001A1 (pt)
MX (1) MX2011008963A (pt)
RU (1) RU2011140219A (pt)
WO (1) WO2010100220A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
KR20120089843A (ko) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010311421B2 (en) 2009-10-29 2014-11-20 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
ES2500048T3 (es) 2010-09-14 2014-09-29 F. Hoffmann-La Roche Ag Procedimiento para purificar eritropoyetina pegilada
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8383093B1 (en) * 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
MY186106A (en) 2012-10-11 2021-06-22 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812507A1 (de) 1988-04-15 1989-10-26 Sachsenwerk Ag Schaltfeld fuer eine gekapselte mittelspannungs-schaltanlage
DE19510438A1 (de) 1995-03-22 1996-09-26 Basf Ag Verfahren zur Herstellung von 1,4-Butandiol und Tetrahydrofuran aus Furan
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker

Also Published As

Publication number Publication date
CN102413843A (zh) 2012-04-11
EP2403537A1 (en) 2012-01-11
JP2012519666A (ja) 2012-08-30
US20120058084A1 (en) 2012-03-08
RU2011140219A (ru) 2013-04-10
WO2010100220A1 (en) 2010-09-10
AU2010220324A1 (en) 2011-09-01
MX2011008963A (es) 2012-02-01
CA2753001A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
NL301211I1 (nl) Olipudase alfa
NL301210I1 (nl) Avalglucosidase alfa
NO2020033I1 (no) andeksanet alfa
SMT201600351B (it) Composti antivirali
FI20095967L (fi) Valaisinsovitelma
EP3832204C0 (en) USER-WEARABLE LIGHTING ASSEMBLY
PL2414015T4 (pl) System laryngoskopowy
HUE032917T2 (hu) 1-es típusú interferon diagnosztikum
EP4220743C0 (en) LIGHT EMITTING DIODE
PT2483389T (pt) Estirpes de shigella com hipervesiculação
BR112012001777A2 (pt) serigrafia
BRPI1010661A2 (pt) peptídeo
NL300948I2 (nl) velmanase alfa
BRPI0922716A2 (pt) purificação de polipeptídeo
FR2947857B1 (fr) Agencement de deshuileur
BR112012001722A2 (pt) projetor de led
DK3696491T3 (da) Leddelt målestok
FI20096192L (fi) Kohteen valaiseminen
DE102009055010A8 (de) Dachanordnung
FI20096108A0 (fi) Järjestely
EP2683644A4 (en) Transport apparatus
FI20090342L (fi) Henkilökuljetin
NO20093038A (no) Skip
CR10574S (es) Bloques alfa
DOS2009000074S (es) Molduras

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01)